Levy Richard S insider trades
Levy Richard S has filed 39 Form 4s with the SEC that we hold, for Madrigal Pharmaceuticals, INC. (MDGL) (Director), Kiniksa Pharmaceuticals International, plc (KNSA) (Director), Kodiak Sciences Inc. (KOD) (Director) and Protara Therapeutics, Inc. (TARA) (Director), among 5 companies in all. Across all of them we count 1 purchase worth $63.8K and 47 sales worth $20.0M reported on Form 4. In the last 12 months: 0 purchases ($0) and 26 sales ($7.4M). The largest single trade was a sale of 5,000 shares of Madrigal Pharmaceuticals, INC. worth $1.8M, dated 2024-11-07. The first filing on our record is dated 2021-07-02 and the latest 2026-08-04.
Madrigal Pharmaceuticals, INC. (MDGL)
| Trade date | Code | Shares | Value as filed | Filed | Source |
|---|---|---|---|---|---|
| 2023-01-17 | S, sale reported on Form 4 | 500 | $148.3K | 2023-01-19 | SEC |
| 2023-01-17 | S, sale reported on Form 4 | 2,325 | $686.9K | 2023-01-19 | SEC |
| 2023-01-17 | S, sale reported on Form 4 | 5,164 | $1.5M | 2023-01-19 | SEC |
| 2023-01-17 | S, sale reported on Form 4 | 3,548 | $1.0M | 2023-01-19 | SEC |
| 2023-01-17 | S, sale reported on Form 4 | 5,227 | $1.5M | 2023-01-19 | SEC |
| 2023-01-17 | S, sale reported on Form 4 | 3,325 | $969.8K | 2023-01-19 | SEC |
| 2023-01-17 | S, sale reported on Form 4 | 1,600 | $464.6K | 2023-01-19 | SEC |
| 2023-01-17 | S, sale reported on Form 4 | 300 | $86.7K | 2023-01-19 | SEC |
| 2023-01-17 | S, sale reported on Form 4 | 400 | $114.8K | 2023-01-19 | SEC |
| 2023-01-17 | S, sale reported on Form 4 | 100 | $28.5K | 2023-01-19 | SEC |
| 2024-04-01 | S, sale reported on Form 4 | 4,387 | $1.1M | 2024-04-03 | SEC |
| 2024-04-01 | S, sale reported on Form 4 | 3,900 | $1.0M | 2024-04-03 | SEC |
| 2024-04-01 | S, sale reported on Form 4 | 713 | $189.1K | 2024-04-03 | SEC |
| 2024-04-01 | S, sale reported on Form 4 | 100 | $25.9K | 2024-04-03 | SEC |
| 2024-04-01 | S, sale reported on Form 4 | 1,600 | $412.7K | 2024-04-03 | SEC |
| 2024-04-01 | S, sale reported on Form 4 | 300 | $80.1K | 2024-04-03 | SEC |
| 2024-11-01 | S, sale reported on Form 4 | 800 | $241.8K | 2024-11-05 | SEC |
| 2024-11-01 | S, sale reported on Form 4 | 1,100 | $331.3K | 2024-11-05 | SEC |
| 2024-11-01 | S, sale reported on Form 4 | 2,800 | $840.3K | 2024-11-05 | SEC |
| 2024-11-01 | S, sale reported on Form 4 | 300 | $91.3K | 2024-11-05 | SEC |
| 2024-11-07 | S, sale reported on Form 4 | 5,000 | $1.8M | 2024-11-08 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 146 | $75.1K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 919 | $473.9K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 645 | $333.8K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 835 | $433.0K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 1,355 | $704.2K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 308 | $160.4K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 1,094 | $570.8K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 1,434 | $749.6K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 811 | $424.7K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 153 | $80.2K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 120 | $63.2K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 200 | $105.6K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 440 | $232.6K | 2025-11-14 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 40 | $21.2K | 2025-11-14 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 80 | $41.6K | 2026-05-22 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 782 | $405.7K | 2026-05-22 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 1,497 | $774.8K | 2026-05-22 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 723 | $373.7K | 2026-05-22 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 657 | $339.0K | 2026-05-22 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 343 | $176.5K | 2026-05-22 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 40 | $20.5K | 2026-05-22 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 439 | $225.0K | 2026-05-22 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 610 | $312.0K | 2026-05-22 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 151 | $77.1K | 2026-05-22 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 40 | $20.3K | 2026-05-22 | SEC |
| 2026-05-22 | S, sale reported on Form 4 | 320 | $162.6K | 2026-05-22 | SEC |
Kiniksa Pharmaceuticals International, plc (KNSA)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Kodiak Sciences Inc. (KOD)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Protara Therapeutics, Inc. (TARA)
| Trade date | Code | Shares | Value as filed | Filed | Source |
|---|---|---|---|---|---|
| 2025-05-14 | P, purchase reported on Form 4 | 20,000 | $63.8K | 2025-05-19 | SEC |
CNST
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1454983) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
